ID   TIF1A_HUMAN             Reviewed;        1050 AA.
AC   O15164; A4D1R7; A4D1R8; O95854;
DT   15-JUL-1999, integrated into UniProtKB/Swiss-Prot.
DT   24-JAN-2001, sequence version 3.
DT   12-OCT-2022, entry version 218.
DE   RecName: Full=Transcription intermediary factor 1-alpha;
DE            Short=TIF1-alpha;
DE            EC=2.3.2.27 {ECO:0000269|PubMed:24820418, ECO:0000269|PubMed:32324863};
DE   AltName: Full=E3 ubiquitin-protein ligase TRIM24;
DE   AltName: Full=RING finger protein 82;
DE   AltName: Full=RING-type E3 ubiquitin transferase TIF1-alpha {ECO:0000305};
DE   AltName: Full=Tripartite motif-containing protein 24;
GN   Name=TRIM24; Synonyms=RNF82, TIF1, TIF1A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT), AND SUBUNIT.
RC   TISSUE=Mammary cancer;
RX   PubMed=9115274; DOI=10.1074/jbc.272.18.12062;
RA   Thenot S., Henriquet C., Rochefort H., Cavailles V.;
RT   "Differential interaction of nuclear receptors with the putative human
RT   transcriptional coactivator hTIF1.";
RL   J. Biol. Chem. 272:12062-12068(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM SHORT).
RX   PubMed=10022127; DOI=10.1038/sj.onc.1202655;
RA   Venturini L., You J., Stadler M., Galien R., Lallemand V., Koken M.H.M.,
RA   Mattei M.-G., Ganser A., Chambon P., Losson R., De The H.;
RT   "TIF1gamma, a novel member of the transcriptional intermediary factor 1
RT   family.";
RL   Oncogene 18:1209-1217(1999).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Retinoblastoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=12690205; DOI=10.1126/science.1083423;
RA   Scherer S.W., Cheung J., MacDonald J.R., Osborne L.R., Nakabayashi K.,
RA   Herbrick J.-A., Carson A.R., Parker-Katiraee L., Skaug J., Khaja R.,
RA   Zhang J., Hudek A.K., Li M., Haddad M., Duggan G.E., Fernandez B.A.,
RA   Kanematsu E., Gentles S., Christopoulos C.C., Choufani S., Kwasnicka D.,
RA   Zheng X.H., Lai Z., Nusskern D.R., Zhang Q., Gu Z., Lu F., Zeesman S.,
RA   Nowaczyk M.J., Teshima I., Chitayat D., Shuman C., Weksberg R.,
RA   Zackai E.H., Grebe T.A., Cox S.R., Kirkpatrick S.J., Rahman N.,
RA   Friedman J.M., Heng H.H.Q., Pelicci P.G., Lo-Coco F., Belloni E.,
RA   Shaffer L.G., Pober B., Morton C.C., Gusella J.F., Bruns G.A.P., Korf B.R.,
RA   Quade B.J., Ligon A.H., Ferguson H., Higgins A.W., Leach N.T.,
RA   Herrick S.R., Lemyre E., Farra C.G., Kim H.-G., Summers A.M., Gripp K.W.,
RA   Roberts W., Szatmari P., Winsor E.J.T., Grzeschik K.-H., Teebi A.,
RA   Minassian B.A., Kere J., Armengol L., Pujana M.A., Estivill X.,
RA   Wilson M.D., Koop B.F., Tosi S., Moore G.E., Boright A.P., Zlotorynski E.,
RA   Kerem B., Kroisel P.M., Petek E., Oscier D.G., Mould S.J., Doehner H.,
RA   Doehner K., Rommens J.M., Vincent J.B., Venter J.C., Li P.W., Mural R.J.,
RA   Adams M.D., Tsui L.-C.;
RT   "Human chromosome 7: DNA sequence and biology.";
RL   Science 300:767-772(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM LONG).
RC   TISSUE=Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   PROTEIN SEQUENCE OF 477-510 (ISOFORM LONG).
RC   TISSUE=Mammary cancer;
RA   Cavailles V.;
RL   Submitted (JAN-1999) to UniProtKB.
RN   [8]
RP   INTERACTION WITH NR3C2.
RX   PubMed=10935545; DOI=10.1210/mend.14.8.0502;
RA   Hellal-Levy C., Fagart J., Souque A., Wurtz J.-M., Moras D.,
RA   Rafestin-Oblin M.-E.;
RT   "Crucial role of the H11-H12 loop in stabilizing the active conformation of
RT   the human mineralocorticoid receptor.";
RL   Mol. Endocrinol. 14:1210-1221(2000).
RN   [9]
RP   CHROMOSOMAL TRANSLOCATION WITH RET.
RC   TISSUE=Thyroid;
RX   PubMed=10439047; DOI=10.1038/sj.onc.1202824;
RA   Klugbauer S., Rabes H.M.;
RT   "The transcription coactivator HTIF1 and a related protein are fused to the
RT   RET receptor tyrosine kinase in childhood papillary thyroid carcinomas.";
RL   Oncogene 18:4388-4393(1999).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-811; SER-1025 AND SER-1028,
RP   AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [11]
RP   FUNCTION.
RX   PubMed=16322096; DOI=10.1210/me.2005-0393;
RA   Teyssier C., Ou C.Y., Khetchoumian K., Losson R., Stallcup M.R.;
RT   "Transcriptional intermediary factor 1alpha mediates physical interaction
RT   and functional synergy between the coactivator-associated arginine
RT   methyltransferase 1 and glucocorticoid receptor-interacting protein 1
RT   nuclear receptor coactivators.";
RL   Mol. Endocrinol. 20:1276-1286(2006).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-667; SER-768; SER-808 AND
RP   SER-811, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [14]
RP   INTERACTION WITH AR.
RX   PubMed=19909775; DOI=10.1016/j.bbamcr.2009.11.001;
RA   Kikuchi M., Okumura F., Tsukiyama T., Watanabe M., Miyajima N., Tanaka J.,
RA   Imamura M., Hatakeyama S.;
RT   "TRIM24 mediates ligand-dependent activation of androgen receptor and is
RT   repressed by a bromodomain-containing protein, BRD7, in prostate cancer
RT   cells.";
RL   Biochim. Biophys. Acta 1793:1828-1836(2009).
RN   [15]
RP   FUNCTION AS E3 UBIQUITIN LIGASE, AND INTERACTION WITH TP53.
RX   PubMed=19556538; DOI=10.1073/pnas.0813177106;
RA   Allton K., Jain A.K., Herz H.M., Tsai W.W., Jung S.Y., Qin J., Bergmann A.,
RA   Johnson R.L., Barton M.C.;
RT   "Trim24 targets endogenous p53 for degradation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 106:11612-11616(2009).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1025 AND SER-1028, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-101; SER-110; SER-768 AND
RP   SER-811, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-744; SER-811; THR-818;
RP   SER-1019; SER-1028 AND SER-1042, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [20]
RP   INTERACTION WITH TRIM16.
RX   PubMed=22629402; DOI=10.1371/journal.pone.0037470;
RA   Bell J.L., Malyukova A., Holien J.K., Koach J., Parker M.W., Kavallaris M.,
RA   Marshall G.M., Cheung B.B.;
RT   "TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other
RT   TRIM family members.";
RL   PLoS ONE 7:E37470-E37470(2012).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22814378; DOI=10.1073/pnas.1210303109;
RA   Van Damme P., Lasa M., Polevoda B., Gazquez C., Elosegui-Artola A.,
RA   Kim D.S., De Juan-Pardo E., Demeyer K., Hole K., Larrea E., Timmerman E.,
RA   Prieto J., Arnesen T., Sherman F., Gevaert K., Aldabe R.;
RT   "N-terminal acetylome analyses and functional insights of the N-terminal
RT   acetyltransferase NatB.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:12449-12454(2012).
RN   [22]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-654; SER-744; SER-811;
RP   SER-1025 AND SER-1028, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [23]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [24]
RP   FUNCTION, INDUCTION BY TP53, CATALYTIC ACTIVITY, PHOSPHORYLATION AT
RP   SER-768, AND MUTAGENESIS OF SER-768.
RX   PubMed=24820418; DOI=10.1128/mcb.01705-12;
RA   Jain A.K., Allton K., Duncan A.D., Barton M.C.;
RT   "TRIM24 is a p53-induced E3-ubiquitin ligase that undergoes ATM-mediated
RT   phosphorylation and autodegradation during DNA damage.";
RL   Mol. Cell. Biol. 34:2695-2709(2014).
RN   [25]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-711; LYS-723 AND LYS-949, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25218447; DOI=10.1038/nsmb.2890;
RA   Hendriks I.A., D'Souza R.C., Yang B., Verlaan-de Vries M., Mann M.,
RA   Vertegaal A.C.;
RT   "Uncovering global SUMOylation signaling networks in a site-specific
RT   manner.";
RL   Nat. Struct. Mol. Biol. 21:927-936(2014).
RN   [26]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-723 AND LYS-741, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25114211; DOI=10.1073/pnas.1413825111;
RA   Impens F., Radoshevich L., Cossart P., Ribet D.;
RT   "Mapping of SUMO sites and analysis of SUMOylation changes induced by
RT   external stimuli.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:12432-12437(2014).
RN   [27]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-702; LYS-723 AND LYS-1041, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25772364; DOI=10.1016/j.celrep.2015.02.033;
RA   Hendriks I.A., Treffers L.W., Verlaan-de Vries M., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "SUMO-2 orchestrates chromatin modifiers in response to DNA damage.";
RL   Cell Rep. 10:1778-1791(2015).
RN   [28]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-723, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25755297; DOI=10.1074/mcp.o114.044792;
RA   Xiao Z., Chang J.G., Hendriks I.A., Sigurdsson J.O., Olsen J.V.,
RA   Vertegaal A.C.;
RT   "System-wide analysis of SUMOylation dynamics in response to replication
RT   stress reveals novel small ubiquitin-like modified target proteins and
RT   acceptor lysines relevant for genome stability.";
RL   Mol. Cell. Proteomics 14:1419-1434(2015).
RN   [29]
RP   SUMOYLATION [LARGE SCALE ANALYSIS] AT LYS-7; LYS-205; LYS-276; LYS-436;
RP   LYS-458; LYS-552; LYS-641; LYS-702; LYS-711; LYS-723; LYS-741; LYS-801;
RP   LYS-810; LYS-875 AND LYS-992, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=28112733; DOI=10.1038/nsmb.3366;
RA   Hendriks I.A., Lyon D., Young C., Jensen L.J., Vertegaal A.C.,
RA   Nielsen M.L.;
RT   "Site-specific mapping of the human SUMO proteome reveals co-modification
RT   with phosphorylation.";
RL   Nat. Struct. Mol. Biol. 24:325-336(2017).
RN   [30]
RP   FUNCTION, SUBCELLULAR LOCATION, AND CATALYTIC ACTIVITY.
RX   PubMed=32324863; DOI=10.1084/jem.20192083;
RA   Zhu Q., Yu T., Gan S., Wang Y., Pei Y., Zhao Q., Pei S., Hao S., Yuan J.,
RA   Xu J., Hou F., Wu X., Peng C., Wu P., Qin J., Xiao Y.;
RT   "TRIM24 facilitates antiviral immunity through mediating K63-linked TRAF3
RT   ubiquitination.";
RL   J. Exp. Med. 217:0-0(2020).
RN   [31]
RP   FUNCTION.
RX   PubMed=33724611; DOI=10.1002/cbin.11592;
RA   Hang Y., Tan L., Chen Q., Liu Q., Jin Y.;
RT   "E3 ubiquitin ligase TRIM24 deficiency promotes NLRP3/caspase-1/IL-1beta-
RT   mediated pyroptosis in endometriosis.";
RL   Cell Biol. Int. 45:1561-1570(2021).
RN   [32]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 891-1012.
RG   RIKEN structural genomics initiative (RSGI);
RT   "Crystal structure of human bromodomain protein.";
RL   Submitted (FEB-2009) to the PDB data bank.
RN   [33]
RP   X-RAY CRYSTALLOGRAPHY (1.7 ANGSTROMS) OF 824-1006 IN COMPLEXES WITH
RP   METHYLATED HISTONE PEPTIDES AND ZINC IONS, FUNCTION, MUTAGENESIS OF
RP   ASP-827; CYS-840 AND 979-PHE-ASN-980, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   INDUCTION.
RX   PubMed=21164480; DOI=10.1038/nature09542;
RA   Tsai W.W., Wang Z., Yiu T.T., Akdemir K.C., Xia W., Winter S., Tsai C.Y.,
RA   Shi X., Schwarzer D., Plunkett W., Aronow B., Gozani O., Fischle W.,
RA   Hung M.C., Patel D.J., Barton M.C.;
RT   "TRIM24 links a non-canonical histone signature to breast cancer.";
RL   Nature 468:927-932(2010).
RN   [34]
RP   VARIANTS [LARGE SCALE ANALYSIS] THR-320; ASN-403; ASN-762 AND SER-1009.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Transcriptional coactivator that interacts with numerous
CC       nuclear receptors and coactivators and modulates the transcription of
CC       target genes. Interacts with chromatin depending on histone H3
CC       modifications, having the highest affinity for histone H3 that is both
CC       unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac).
CC       Has E3 protein-ubiquitin ligase activity. During the DNA damage
CC       response, participates in an autoregulatory feedback loop with TP53.
CC       Early in response to DNA damage, ATM kinase phosphorylates TRIM24
CC       leading to its ubiquitination and degradation. After sufficient DNA
CC       repair has occurred, TP53 activates TRIM24 transcription, ultimately
CC       leading to TRIM24-mediated TP53 ubiquitination and degradation
CC       (PubMed:24820418). Plays a role in the regulation of cell proliferation
CC       and apoptosis, at least in part via its effects on p53/TP53 levels. Up-
CC       regulates ligand-dependent transcription activation by AR, GCR/NR3C1,
CC       thyroid hormone receptor (TR) and ESR1. Modulates transcription
CC       activation by retinoic acid (RA) receptors, including RARA. Plays a
CC       role in regulating retinoic acid-dependent proliferation of hepatocytes
CC       (By similarity). Participates also in innate immunity by mediating the
CC       specific 'Lys-63'-linked ubiquitination of TRAF3 leading to activation
CC       of downstream signal transduction of the type I IFN pathway
CC       (PubMed:32324863). Additionally, negatively regulates NLRP3/CASP1/IL-
CC       1beta-mediated pyroptosis and cell migration probably by ubiquitinating
CC       NLRP3 (PubMed:33724611). {ECO:0000250, ECO:0000269|PubMed:16322096,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:21164480,
CC       ECO:0000269|PubMed:24820418, ECO:0000269|PubMed:32324863,
CC       ECO:0000269|PubMed:33724611}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=S-ubiquitinyl-[E2 ubiquitin-conjugating enzyme]-L-cysteine +
CC         [acceptor protein]-L-lysine = [E2 ubiquitin-conjugating enzyme]-L-
CC         cysteine + N(6)-ubiquitinyl-[acceptor protein]-L-lysine.;
CC         EC=2.3.2.27; Evidence={ECO:0000269|PubMed:24820418,
CC         ECO:0000269|PubMed:32324863};
CC   -!- PATHWAY: Protein modification; protein ubiquitination.
CC   -!- SUBUNIT: Interacts with CARM1, NCOA2/GRIP1, PML, KAT5/TIP60, BRD7,
CC       CBX1, CBX3 and CBX5. Part of a coactivator complex containing TRIM24,
CC       NCOA2 and CARM1 (By similarity). Interacts with NR3C2/MCR. Interacts
CC       with the ligand-binding domain of estrogen receptors (in vitro).
CC       Interaction with DNA-bound estrogen receptors requires the presence of
CC       estradiol. Interacts with AR and p53/TP53. Interacts (via bromo domain)
CC       with histone H3 (via N-terminus), provided that it is not methylated at
CC       'Lys-4' (H3K4me0). Does not interact with histone H3 that is methylated
CC       at 'Lys-4' (H3K4me1, H3K4me2 or H3K4me3). Interacts (via bromo domain)
CC       with histone H3 (via N-terminus) that is acetylated at 'Lys-23'
CC       (H3K23ac). Has the highest affinity for histone H3 that is both
CC       unmodified at 'Lys-4' (H3K4me0) and acetylated at 'Lys-23' (H3K23ac).
CC       Has very low affinity for histone H3 that is methylated at 'Lys-9'
CC       (H3K9me), or acetylated at both 'Lys-9' (H3K9ac) and 'Lys-14'
CC       (H3K14ac), or acetylated at 'Lys-27' (H3K27ac) (in vitro). Interacts
CC       with TRIM16. {ECO:0000250, ECO:0000269|PubMed:10935545,
CC       ECO:0000269|PubMed:19556538, ECO:0000269|PubMed:19909775,
CC       ECO:0000269|PubMed:21164480, ECO:0000269|PubMed:22629402,
CC       ECO:0000269|PubMed:9115274}.
CC   -!- INTERACTION:
CC       O15164; P03372: ESR1; NbExp=3; IntAct=EBI-2130378, EBI-78473;
CC       O15164; P04637: TP53; NbExp=3; IntAct=EBI-2130378, EBI-366083;
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:21164480,
CC       ECO:0000269|PubMed:32324863}. Cytoplasm {ECO:0000269|PubMed:21164480}.
CC       Mitochondrion {ECO:0000269|PubMed:32324863}. Note=Colocalizes with
CC       sites of active transcription. Detected both in nucleus and cytoplasm
CC       in some breast cancer samples. Predominantly nuclear. Translocated from
CC       nucleus to mitochondria to mediate antiviral immunity
CC       (PubMed:32324863). {ECO:0000269|PubMed:32324863}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=Long;
CC         IsoId=O15164-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=O15164-2; Sequence=VSP_005772;
CC   -!- INDUCTION: Up-regulated in some cases of breast cancer
CC       (PubMed:21164480). Expression is induced by damage-activated TP53
CC       (PubMed:24820418). {ECO:0000269|PubMed:21164480,
CC       ECO:0000269|PubMed:24820418}.
CC   -!- PTM: Phosphorylated at Ser-768 by ATM kinase induces ubiquitination and
CC       degradation during DNA damage. {ECO:0000269|PubMed:24820418}.
CC   -!- PTM: Sumoylated. {ECO:0000250|UniProtKB:Q64127}.
CC   -!- PTM: Undergoes ubiquitination-mediated degradation in response to DNA
CC       damage. {ECO:0000269|PubMed:24820418}.
CC   -!- DISEASE: Note=A chromosomal aberration involving TRIM24/TIF1 is found
CC       in papillary thyroid carcinomas (PTCs). Translocation t(7;10)(q32;q11)
CC       with RET. The translocation generates the TRIM24/RET (PTC6) oncogene.
CC       {ECO:0000269|PubMed:10439047}.
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/TRIM24ID504ch7q34.html";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF009353; AAB63585.1; -; mRNA.
DR   EMBL; AF119042; AAD17258.1; -; mRNA.
DR   EMBL; AK075306; BAG52105.1; -; mRNA.
DR   EMBL; AC008265; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC013429; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH236950; EAL24046.1; -; Genomic_DNA.
DR   EMBL; CH236950; EAL24047.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83884.1; -; Genomic_DNA.
DR   EMBL; CH471070; EAW83885.1; -; Genomic_DNA.
DR   EMBL; BC028689; AAH28689.2; -; mRNA.
DR   CCDS; CCDS47720.1; -. [O15164-2]
DR   CCDS; CCDS5847.1; -. [O15164-1]
DR   RefSeq; NP_003843.3; NM_003852.3. [O15164-2]
DR   RefSeq; NP_056989.2; NM_015905.2. [O15164-1]
DR   PDB; 2YYN; X-ray; 2.50 A; A/B/C/D=891-1012.
DR   PDB; 3O33; X-ray; 2.00 A; A/B/C/D=824-1006.
DR   PDB; 3O34; X-ray; 1.90 A; A=824-1006.
DR   PDB; 3O35; X-ray; 1.76 A; A/B=824-1006.
DR   PDB; 3O36; X-ray; 1.70 A; A/B=824-1006.
DR   PDB; 3O37; X-ray; 2.00 A; A/B/C/D=824-1006.
DR   PDB; 4YAB; X-ray; 1.90 A; A/B=824-1006.
DR   PDB; 4YAD; X-ray; 1.73 A; A/B=824-1006.
DR   PDB; 4YAT; X-ray; 2.18 A; A/B=824-1006.
DR   PDB; 4YAX; X-ray; 2.25 A; A/B=824-1006.
DR   PDB; 4YBM; X-ray; 1.46 A; A/B=824-1006.
DR   PDB; 4YBS; X-ray; 1.83 A; A=824-1006.
DR   PDB; 4YBT; X-ray; 1.82 A; A=824-1006.
DR   PDB; 4YC9; X-ray; 1.82 A; A=824-1006.
DR   PDB; 4ZQL; X-ray; 1.79 A; A/B=825-1006.
DR   PDB; 5H1T; X-ray; 1.95 A; A/B/C/D=824-1006.
DR   PDB; 5H1U; X-ray; 1.90 A; A/B/C/D=824-1006.
DR   PDB; 5H1V; X-ray; 2.00 A; A/B=824-1006.
DR   PDB; 7B9X; NMR; -; A=901-1006.
DR   PDBsum; 2YYN; -.
DR   PDBsum; 3O33; -.
DR   PDBsum; 3O34; -.
DR   PDBsum; 3O35; -.
DR   PDBsum; 3O36; -.
DR   PDBsum; 3O37; -.
DR   PDBsum; 4YAB; -.
DR   PDBsum; 4YAD; -.
DR   PDBsum; 4YAT; -.
DR   PDBsum; 4YAX; -.
DR   PDBsum; 4YBM; -.
DR   PDBsum; 4YBS; -.
DR   PDBsum; 4YBT; -.
DR   PDBsum; 4YC9; -.
DR   PDBsum; 4ZQL; -.
DR   PDBsum; 5H1T; -.
DR   PDBsum; 5H1U; -.
DR   PDBsum; 5H1V; -.
DR   PDBsum; 7B9X; -.
DR   AlphaFoldDB; O15164; -.
DR   SMR; O15164; -.
DR   BioGRID; 114333; 288.
DR   DIP; DIP-52713N; -.
DR   ELM; O15164; -.
DR   IntAct; O15164; 145.
DR   MINT; O15164; -.
DR   STRING; 9606.ENSP00000340507; -.
DR   BindingDB; O15164; -.
DR   ChEMBL; CHEMBL3108638; -.
DR   GuidetoPHARMACOLOGY; 2252; -.
DR   GlyGen; O15164; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; O15164; -.
DR   MetOSite; O15164; -.
DR   PhosphoSitePlus; O15164; -.
DR   BioMuta; TRIM24; -.
DR   EPD; O15164; -.
DR   jPOST; O15164; -.
DR   MassIVE; O15164; -.
DR   MaxQB; O15164; -.
DR   PaxDb; O15164; -.
DR   PeptideAtlas; O15164; -.
DR   PRIDE; O15164; -.
DR   ProteomicsDB; 48484; -. [O15164-1]
DR   ProteomicsDB; 48485; -. [O15164-2]
DR   ABCD; O15164; 1 sequenced antibody.
DR   Antibodypedia; 32326; 562 antibodies from 38 providers.
DR   DNASU; 8805; -.
DR   Ensembl; ENST00000343526.9; ENSP00000340507.4; ENSG00000122779.18. [O15164-1]
DR   Ensembl; ENST00000415680.6; ENSP00000390829.2; ENSG00000122779.18. [O15164-2]
DR   GeneID; 8805; -.
DR   KEGG; hsa:8805; -.
DR   MANE-Select; ENST00000343526.9; ENSP00000340507.4; NM_015905.3; NP_056989.2.
DR   UCSC; uc003vub.4; human. [O15164-1]
DR   CTD; 8805; -.
DR   DisGeNET; 8805; -.
DR   GeneCards; TRIM24; -.
DR   HGNC; HGNC:11812; TRIM24.
DR   HPA; ENSG00000122779; Low tissue specificity.
DR   MalaCards; TRIM24; -.
DR   MIM; 603406; gene.
DR   neXtProt; NX_O15164; -.
DR   OpenTargets; ENSG00000122779; -.
DR   Orphanet; 146; Differentiated thyroid carcinoma.
DR   PharmGKB; PA36519; -.
DR   VEuPathDB; HostDB:ENSG00000122779; -.
DR   eggNOG; KOG2177; Eukaryota.
DR   GeneTree; ENSGT00940000159863; -.
DR   HOGENOM; CLU_005817_0_1_1; -.
DR   InParanoid; O15164; -.
DR   OMA; WIGPSHT; -.
DR   OrthoDB; 756911at2759; -.
DR   PhylomeDB; O15164; -.
DR   TreeFam; TF106455; -.
DR   PathwayCommons; O15164; -.
DR   Reactome; R-HSA-1839117; Signaling by cytosolic FGFR1 fusion mutants.
DR   Reactome; R-HSA-5655302; Signaling by FGFR1 in disease.
DR   Reactome; R-HSA-6802952; Signaling by BRAF and RAF1 fusions.
DR   SignaLink; O15164; -.
DR   SIGNOR; O15164; -.
DR   UniPathway; UPA00143; -.
DR   BioGRID-ORCS; 8805; 30 hits in 1139 CRISPR screens.
DR   ChiTaRS; TRIM24; human.
DR   EvolutionaryTrace; O15164; -.
DR   GeneWiki; TRIM24; -.
DR   GenomeRNAi; 8805; -.
DR   Pharos; O15164; Tchem.
DR   PRO; PR:O15164; -.
DR   Proteomes; UP000005640; Chromosome 7.
DR   RNAct; O15164; protein.
DR   Bgee; ENSG00000122779; Expressed in sperm and 212 other tissues.
DR   ExpressionAtlas; O15164; baseline and differential.
DR   Genevisible; O15164; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0000791; C:euchromatin; IEA:Ensembl.
DR   GO; GO:0001673; C:male germ cell nucleus; IEA:Ensembl.
DR   GO; GO:0005739; C:mitochondrion; IEA:UniProtKB-SubCell.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:UniProtKB.
DR   GO; GO:0005726; C:perichromatin fibrils; IEA:Ensembl.
DR   GO; GO:0003682; F:chromatin binding; IDA:UniProtKB.
DR   GO; GO:0034056; F:estrogen response element binding; IDA:UniProtKB.
DR   GO; GO:0070577; F:lysine-acetylated histone binding; IDA:UniProtKB.
DR   GO; GO:0016922; F:nuclear receptor binding; IEA:Ensembl.
DR   GO; GO:0002039; F:p53 binding; IPI:UniProtKB.
DR   GO; GO:0004672; F:protein kinase activity; IEA:Ensembl.
DR   GO; GO:0005102; F:signaling receptor binding; TAS:ProtInc.
DR   GO; GO:0003713; F:transcription coactivator activity; IDA:UniProtKB.
DR   GO; GO:0061630; F:ubiquitin protein ligase activity; IDA:UniProtKB.
DR   GO; GO:0008270; F:zinc ion binding; IDA:UniProtKB.
DR   GO; GO:0055074; P:calcium ion homeostasis; IEA:Ensembl.
DR   GO; GO:0071391; P:cellular response to estrogen stimulus; IDA:UniProtKB.
DR   GO; GO:0050673; P:epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0045892; P:negative regulation of DNA-templated transcription; IEA:Ensembl.
DR   GO; GO:0050680; P:negative regulation of epithelial cell proliferation; IEA:Ensembl.
DR   GO; GO:0010628; P:positive regulation of gene expression; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IEA:Ensembl.
DR   GO; GO:0030163; P:protein catabolic process; IMP:UniProtKB.
DR   GO; GO:0016567; P:protein ubiquitination; IDA:UniProtKB.
DR   GO; GO:0042981; P:regulation of apoptotic process; IMP:UniProtKB.
DR   GO; GO:0031647; P:regulation of protein stability; IMP:UniProtKB.
DR   GO; GO:1901796; P:regulation of signal transduction by p53 class mediator; IEA:Ensembl.
DR   GO; GO:0070562; P:regulation of vitamin D receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0006366; P:transcription by RNA polymerase II; TAS:ProtInc.
DR   Gene3D; 1.20.920.10; -; 1.
DR   Gene3D; 3.30.40.10; -; 2.
DR   IDEAL; IID00289; -.
DR   InterPro; IPR003649; Bbox_C.
DR   InterPro; IPR001487; Bromodomain.
DR   InterPro; IPR036427; Bromodomain-like_sf.
DR   InterPro; IPR018359; Bromodomain_CS.
DR   InterPro; IPR019786; Zinc_finger_PHD-type_CS.
DR   InterPro; IPR000315; Znf_B-box.
DR   InterPro; IPR011011; Znf_FYVE_PHD.
DR   InterPro; IPR001965; Znf_PHD.
DR   InterPro; IPR019787; Znf_PHD-finger.
DR   InterPro; IPR001841; Znf_RING.
DR   InterPro; IPR013083; Znf_RING/FYVE/PHD.
DR   InterPro; IPR017907; Znf_RING_CS.
DR   Pfam; PF00439; Bromodomain; 1.
DR   Pfam; PF00628; PHD; 1.
DR   Pfam; PF00643; zf-B_box; 1.
DR   PRINTS; PR00503; BROMODOMAIN.
DR   SMART; SM00502; BBC; 1.
DR   SMART; SM00336; BBOX; 2.
DR   SMART; SM00297; BROMO; 1.
DR   SMART; SM00249; PHD; 1.
DR   SMART; SM00184; RING; 1.
DR   SUPFAM; SSF47370; SSF47370; 1.
DR   SUPFAM; SSF57903; SSF57903; 1.
DR   PROSITE; PS00633; BROMODOMAIN_1; 1.
DR   PROSITE; PS50014; BROMODOMAIN_2; 1.
DR   PROSITE; PS50119; ZF_BBOX; 2.
DR   PROSITE; PS01359; ZF_PHD_1; 1.
DR   PROSITE; PS50016; ZF_PHD_2; 1.
DR   PROSITE; PS00518; ZF_RING_1; 1.
DR   PROSITE; PS50089; ZF_RING_2; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Bromodomain; Chromosomal rearrangement;
KW   Coiled coil; Cytoplasm; Direct protein sequencing; DNA-binding;
KW   Isopeptide bond; Metal-binding; Methylation; Mitochondrion; Nucleus;
KW   Phosphoprotein; Reference proteome; Repeat; Repressor; Transcription;
KW   Transcription regulation; Transferase; Tumor suppressor; Ubl conjugation;
KW   Ubl conjugation pathway; Zinc; Zinc-finger.
FT   CHAIN           1..1050
FT                   /note="Transcription intermediary factor 1-alpha"
FT                   /id="PRO_0000056390"
FT   DOMAIN          932..987
FT                   /note="Bromo"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00035"
FT   ZN_FING         56..82
FT                   /note="RING-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00175"
FT   ZN_FING         158..211
FT                   /note="B box-type 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         218..259
FT                   /note="B box-type 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   ZN_FING         826..873
FT                   /note="PHD-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00146"
FT   REGION          15..44
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          429..456
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          476..550
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          571..594
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          643..712
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          754..779
FT                   /note="Nuclear receptor binding site (NRBS)"
FT   REGION          766..824
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          834..840
FT                   /note="Interaction with histone H3 that is not methylated
FT                   at 'Lys-4' (H3K4me0)"
FT   REGION          979..980
FT                   /note="Interaction with histone H3 that is acetylated at
FT                   'Lys-23' (H3K23ac)"
FT   REGION          1011..1036
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          289..359
FT                   /evidence="ECO:0000255"
FT   MOTIF           891..907
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        431..456
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        499..525
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        526..540
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        648..671
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        680..706
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        766..806
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   BINDING         163
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         166
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         187
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         200
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         223
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         226
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         246
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   BINDING         251
FT                   /ligand="Zn(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29105"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00024"
FT   SITE            476..477
FT                   /note="Breakpoint for translocation to form TRIM24-RET
FT                   oncogene"
FT   SITE            827
FT                   /note="Interaction with histone H3 that is not methylated
FT                   at 'Lys-4' (H3K4me0)"
FT   MOD_RES         101
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         110
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:20068231"
FT   MOD_RES         469
FT                   /note="Omega-N-methylarginine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64127"
FT   MOD_RES         654
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         660
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q64127"
FT   MOD_RES         667
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         744
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         768
FT                   /note="Phosphoserine; by ATM"
FT                   /evidence="ECO:0000269|PubMed:24820418,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231"
FT   MOD_RES         808
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         811
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:21406692, ECO:0007744|PubMed:23186163"
FT   MOD_RES         818
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1019
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   MOD_RES         1025
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:23186163"
FT   MOD_RES         1028
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:19690332, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         1042
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692"
FT   CROSSLNK        7
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        205
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        276
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        436
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        458
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        552
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        641
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        702
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        711
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO1); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211"
FT   CROSSLNK        723
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2); alternate"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:25218447, ECO:0007744|PubMed:25755297,
FT                   ECO:0007744|PubMed:25772364, ECO:0007744|PubMed:28112733"
FT   CROSSLNK        741
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25114211,
FT                   ECO:0007744|PubMed:28112733"
FT   CROSSLNK        801
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        810
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        875
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        949
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25218447"
FT   CROSSLNK        992
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:28112733"
FT   CROSSLNK        1041
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in SUMO2)"
FT                   /evidence="ECO:0007744|PubMed:25772364"
FT   VAR_SEQ         477..510
FT                   /note="Missing (in isoform Short)"
FT                   /evidence="ECO:0000303|PubMed:10022127,
FT                   ECO:0000303|PubMed:9115274"
FT                   /id="VSP_005772"
FT   VARIANT         320
FT                   /note="I -> T (in an ovarian serous carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042382"
FT   VARIANT         403
FT                   /note="T -> N (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042383"
FT   VARIANT         762
FT                   /note="S -> N"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042384"
FT   VARIANT         796
FT                   /note="N -> S (in dbSNP:rs35356723)"
FT                   /id="VAR_052148"
FT   VARIANT         1009
FT                   /note="R -> S (in dbSNP:rs34585297)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_042385"
FT   MUTAGEN         768
FT                   /note="S->A: Ubiquitination is significantly lower than
FT                   wild-type."
FT                   /evidence="ECO:0000269|PubMed:24820418"
FT   MUTAGEN         827
FT                   /note="D->A: Strongly reduced affinity for histone H3 that
FT                   is not methylated at 'Lys-4' (H3K4me0)."
FT                   /evidence="ECO:0000269|PubMed:21164480"
FT   MUTAGEN         840
FT                   /note="C->W: Abolishes interaction with histone H3."
FT                   /evidence="ECO:0000269|PubMed:21164480"
FT   MUTAGEN         979..980
FT                   /note="FN->AA: Strongly reduced affinity for histone H3
FT                   that is acetylated at 'Lys-23' (H3K23ac)."
FT                   /evidence="ECO:0000269|PubMed:21164480"
FT   CONFLICT        14..20
FT                   /note="AASAAAS -> RLGCAP (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        24..28
FT                   /note="SAAPS -> RGG (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        109..114
FT                   /note="GSPVSG -> ARRSA (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        350
FT                   /note="A -> T (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="D -> N (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        608
FT                   /note="M -> I (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        967
FT                   /note="A -> R (in Ref. 1; AAB63585)"
FT                   /evidence="ECO:0000305"
FT   STRAND          827..829
FT                   /evidence="ECO:0007829|PDB:3O33"
FT   TURN            830..832
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   STRAND          836..840
FT                   /evidence="ECO:0007829|PDB:3O37"
FT   STRAND          842..845
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   TURN            850..852
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   STRAND          853..855
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   TURN            868..870
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   STRAND          873..875
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   HELIX           881..883
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   TURN            889..891
FT                   /evidence="ECO:0007829|PDB:3O36"
FT   HELIX           902..917
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   HELIX           919..921
FT                   /evidence="ECO:0007829|PDB:3O37"
FT   HELIX           922..924
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   HELIX           935..938
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   HELIX           945..953
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   TURN            954..956
FT                   /evidence="ECO:0007829|PDB:4YC9"
FT   HELIX           962..979
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   HELIX           985..1004
FT                   /evidence="ECO:0007829|PDB:4YBM"
FT   STRAND          1005..1007
FT                   /evidence="ECO:0007829|PDB:2YYN"
SQ   SEQUENCE   1050 AA;  116831 MW;  D341E8022AACC67E CRC64;
     MEVAVEKAVA AAAAASAAAS GGPSAAPSGE NEAESRQGPD SERGGEAARL NLLDTCAVCH
     QNIQSRAPKL LPCLHSFCQR CLPAPQRYLM LPAPMLGSAE TPPPVPAPGS PVSGSSPFAT
     QVGVIRCPVC SQECAERHII DNFFVKDTTE VPSSTVEKSN QVCTSCEDNA EANGFCVECV
     EWLCKTCIRA HQRVKFTKDH TVRQKEEVSP EAVGVTSQRP VFCPFHKKEQ LKLYCETCDK
     LTCRDCQLLE HKEHRYQFIE EAFQNQKVII DTLITKLMEK TKYIKFTGNQ IQNRIIEVNQ
     NQKQVEQDIK VAIFTLMVEI NKKGKALLHQ LESLAKDHRM KLMQQQQEVA GLSKQLEHVM
     HFSKWAVSSG SSTALLYSKR LITYRLRHLL RARCDASPVT NNTIQFHCDP SFWAQNIINL
     GSLVIEDKES QPQMPKQNPV VEQNSQPPSG LSSNQLSKFP TQISLAQLRL QHMQQQVMAQ
     RQQVQRRPAP VGLPNPRMQG PIQQPSISHQ QPPPRLINFQ NHSPKPNGPV LPPHPQQLRY
     PPNQNIPRQA IKPNPLQMAF LAQQAIKQWQ ISSGQGTPST TNSTSSTPSS PTITSAAGYD
     GKAFGSPMID LSSPVGGSYN LPSLPDIDCS STIMLDNIVR KDTNIDHGQP RPPSNRTVQS
     PNSSVPSPGL AGPVTMTSVH PPIRSPSASS VGSRGSSGSS SKPAGADSTH KVPVVMLEPI
     RIKQENSGPP ENYDFPVVIV KQESDEESRP QNANYPRSIL TSLLLNSSQS STSEETVLRS
     DAPDSTGDQP GLHQDNSSNG KSEWLDPSQK SPLHVGETRK EDDPNEDWCA VCQNGGELLC
     CEKCPKVFHL SCHVPTLTNF PSGEWICTFC RDLSKPEVEY DCDAPSHNSE KKKTEGLVKL
     TPIDKRKCER LLLFLYCHEM SLAFQDPVPL TVPDYYKIIK NPMDLSTIKK RLQEDYSMYS
     KPEDFVADFR LIFQNCAEFN EPDSEVANAG IKLENYFEEL LKNLYPEKRF PKPEFRNESE
     DNKFSDDSDD DFVQPRKKRL KSIEERQLLK
//
